FDA-cleared profile

Hyper Insight - ICH

SK Inc. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Notification-only triage for suspected acute intracranial hemorrhage on non-contrast brain CT, sharing cases with medical specialists in parallel with standard care.

Clinical role
Parallel notification and worklist-prioritization tool; returns suspected ICH or case-processed status to a PACS/workstation and mobile preview workflow while the specialist performs full diagnostic interpretation.
Images and patients
CT/CTA · Brain
Key limitation
Keep in mind: Notification and preview are not diagnostic and cannot substitute for full patient assessment or diagnostic-viewer interpretation. The packet states a GE-scanner contraindication for otherwise eligible non-contrast CT and requires specialist review; exact current deployment, security, and interface versions are not established.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Notification-only triage for suspected acute intracranial hemorrhage on non-contrast brain CT, sharing cases with medical specialists in parallel with standard care.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Brain Input: DICOM non-contrast head CT images. The FDA packet states a contraindication for analyzing otherwise eligible non-contrast CT scans acquired on scanners from manufacturers other than General Electric or its subsidiaries.
  • Who uses it?Intended users: Radiologists, emergency-medicine physicians, neurosurgeons, neurologists, and other trained clinicians or medical specialists.
  • What does the software produce?Output: A binary suspected-ICH or case-processed result, no image marking, and a non-diagnostic preview or notification delivered through the worklist, PACS/workstation, or mobile application for specialist review.
  • What is its most important limitation?Key limitation: Notification and preview are not diagnostic and cannot substitute for full patient assessment or diagnostic-viewer interpretation. The packet states a GE-scanner contraindication for otherwise eligible non-contrast CT and requires specialist review; exact current deployment, security, and interface versions are not established.

Clinical takeaway. Clinical role: Notification-only triage for suspected acute intracranial hemorrhage on non-contrast brain CT, sharing cases with medical specialists in parallel with standard care.

Evidence takeaway. Evidence from the reviewed source record: FDA retrospective testing used 394 brain CT images from 13 U.S. clinical sites, including 198 ICH-positive and 196 ICH-negative images, with ground truth established by trained neuro-radiologists and a reference-standard committee. Subject sensitivity was 95.45% (95% CI 91.55%-97.90%), specificity was 98.47% (95% CI 95.59%-99.68%), AUC was 0.9864 (95% CI 0.9738-0.9989), and mean time to notification was 16.39 +/- 5.46 seconds. The pre-specified sensitivity and specificity performance goal was 80%.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Notification-only triage for suspected acute intracranial hemorrhage on non-contrast brain CT, sharing cases with medical specialists in parallel with standard care.
  • Exact FDA submission
  • Checked 2026-09-08
Workflow role
Parallel notification and worklist-prioritization tool; returns suspected ICH or case-processed status to a PACS/workstation and mobile preview workflow while the specialist performs full diagnostic interpretation.
  • Exact FDA submission
  • Checked 2026-09-08
Required input
DICOM non-contrast head CT images. The FDA packet states a contraindication for analyzing otherwise eligible non-contrast CT scans acquired on scanners from manufacturers other than General Electric or its subsidiaries.
  • Exact FDA submission
  • Checked 2026-09-08
Output and clinician action
A binary suspected-ICH or case-processed result, no image marking, and a non-diagnostic preview or notification delivered through the worklist, PACS/workstation, or mobile application for specialist review.
  • Exact FDA submission
  • Checked 2026-09-08
Care setting
Clinical or hospital environment, including acute neuroimaging and emergency triage workflow.
  • Exact FDA submission
  • Checked 2026-09-08
Intended users
Radiologists, emergency-medicine physicians, neurosurgeons, neurologists, and other trained clinicians or medical specialists.
  • Exact FDA submission
  • Checked 2026-09-08
Limitations
Notification and preview are not diagnostic and cannot substitute for full patient assessment or diagnostic-viewer interpretation. The packet states a GE-scanner contraindication for otherwise eligible non-contrast CT and requires specialist review; exact current deployment, security, and interface versions are not established.
  • Exact FDA submission
  • Checked 2026-09-08
Evidence summary
FDA retrospective testing used 394 brain CT images from 13 U.S. clinical sites, including 198 ICH-positive and 196 ICH-negative images, with ground truth established by trained neuro-radiologists and a reference-standard committee. Subject sensitivity was 95.45% (95% CI 91.55%-97.90%), specificity was 98.47% (95% CI 95.59%-99.68%), AUC was 0.9864 (95% CI 0.9738-0.9989), and mean time to notification was 16.39 +/- 5.46 seconds. The pre-specified sensitivity and specificity performance goal was 80%.
  • Exact FDA submission
  • Checked 2026-09-08

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA retrospective testing used 394 brain CT images from 13 U.S. clinical sites, including 198 ICH-positive and 196 ICH-negative images, with ground truth established by trained neuro-radiologists and a reference-standard committee. Subject sensitivity was 95.45% (95% CI 91.55%-97.90%), specificity was 98.47% (95% CI 95.59%-99.68%), AUC was 0.9864 (95% CI 0.9738-0.9989), and mean time to notification was 16.39 +/- 5.46 seconds. The pre-specified sensitivity and specificity performance goal was 80%.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Reported sensitivity
95.45% (95% CI: 91.55%, 97.90%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model sensitivity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

Reported specificity
98.47% (95% CI: 95.59%, 99.68%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model specificity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

Hyper Insight - ICH regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationPopulation described in the exact-submission ACR model card
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K240353
  • Samplen=394
  • Sites13
  • IndependenceIndependence not established

K240353

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K240353. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM non-contrast head CT images. The FDA packet states a contraindication for analyzing otherwise eligible non-contrast CT scans acquired on scanners from manufacturers other than General Electric or its subsidiaries.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-08 · FDA K240353: Hyper Insight - ICH

  2. Routing

    Source context, not route validation: A third-party worklist application receives analysis requests and DICOM images and receives the ICH finding back for radiologist alerts; the comparison table identifies DICOM compatibility, PACS/workstation results, and mobile non-diagnostic preview.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-08 · FDA K240353: Hyper Insight - ICH

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 ·

  4. Returned objects

    Source context, not route validation: A binary suspected-ICH or case-processed result, no image marking, and a non-diagnostic preview or notification delivered through the worklist, PACS/workstation, or mobile application for specialist review.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-08 · FDA K240353: Hyper Insight - ICH

  5. Viewer/worklist/report

    Unresolved route: A binary suspected-ICH or case-processed result, no image marking, and a non-diagnostic preview or notification delivered through the worklist, PACS/workstation, or mobile application for specialist review.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-08 · FDA K240353: Hyper Insight - ICH

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
A third-party worklist application receives analysis requests and DICOM images and receives the ICH finding back for radiologist alerts; the comparison table identifies DICOM compatibility, PACS/workstation results, and mobile non-diagnostic preview.
  • Exact FDA submission
  • Checked 2026-09-08

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

Result destination

PACS and workstation are explicitly referenced as a result destination.

exact submission · checked 2026-09-01

Confirm supported products, versions, routing behavior, and display requirements during local evaluation.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for Hyper Insight - ICH; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-08
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K240353
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Anatomy
Brain
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-07-01
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
24Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact K240353 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Deployment: Not publicly available - checked 2026-11-14 - Exact FDA submission

    The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-08 - Exact FDA submission

    Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-08 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 3 history items

Source ledger

  1. FDA K240353: Hyper Insight - ICH

    U.S. Food and Drug Administration - Published 2024-07-01 - Accessed 2026-09-08

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Hyper Insight - ICH model card (K240353)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, output, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K240353

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

Research history

  1. K240353 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K251590

Methinks CTA Stroke

Methinks Software S.L.

Authorized purpose: Methinks CTA Stroke analyzes acute-setting brain CT angiography in adults over 21 with suspected stroke for suspected large-vessel occlusion in the terminal ICA, MCA-M1, or MCA-M2 and sends PACS and/or specialist notifications in parallel to standard care; previews are informational and not diagnostic.

Modality
CT/CTA
Anatomy
Brain
Decision
2025-08-20
FDA-cleared K251151

Rapid CTA 360

iSchemaView

Authorized purpose: Rapid CTA 360 analyzes adult head CTA DICOM images to flag suspected large- and medium-vessel occlusion in specified intracranial and vertebral segments and notify trained clinicians for workflow triage; notifications are informational and not diagnostic.

Modality
CT/CTA
Anatomy
Brain
Decision
2025-07-16
FDA-cleared K250685

Methinks NCCT Stroke

Methinks Software S.L.

Authorized purpose: Methinks NCCT Stroke analyzes adult non-contrast head CT to flag suspected intracranial hemorrhage and suspected large-vessel occlusion of the ICA, MCA-M1, or MCA-M2 for parallel workflow triage via PACS and/or notifications; previews are informational, not diagnostic, and a negative notification does not rule out LVO or replace CTA/standard care.

Modality
CT/CTA
Anatomy
Brain
Decision
2025-06-16

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history